# CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

> **NCT03387592** · PHASE2 · TERMINATED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 53 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** CPT-11
- **DRUG:** Calcio levofolinate
- **DRUG:** 5-Fluorouracil
- **DRUG:** Capecitabine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03387592
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-06
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Efficacy endpoint not met according to first step of Briant-Day design
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387592, "CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03387592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*